Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Targeting CD117 with engineered invariant natural killer T cells (iNKT Cells) as a novel approach for acute myeloid leukemia treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

HYHao YanQBQuenton R. BubbRNRobert S. Negrin

Discussion

Loading...

Member takes

Overview

Experimental therapy targeting CD117 with iNKT cells improves survival in acute myeloid leukemia, indicating promising adoptive cell therapy potential.

Key Points

  • CD117-targeted iNKT cells showed improved cytotoxicity against leukemia, enhancing treatment outcomes.
  • Significant median survival of 58 days observed in NSG mice treated with CAR-iNKT cells versus 50 days for controls.
  • Assessment involved bioluminescent imaging to monitor tumor burden throughout the study.
  • Absence of graft-versus-host disease supports the safety of this engineered iNKT cell approach.

Cite This Study

Yan et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d648https://doi.org/10.1182/blood-2025-7662
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia2025 · 9 citations
  2. 2Novel allogeneic BCMA CAR-expressing iNKT cells with PD1 deletion demonstrate superior tumor control in a multiple myeloma preclinical model2025
  3. 3Effiefficacy and safety of allogeneic CD123 CAR-NK cell therapy in Relapsed/Refractory Acute Myeloid Leukemia2025 · 3 citations
  4. 4Enhanced VLA4-dependent endothelial cell adhesion underpins the higher efficacy of CAR-iNKT over CAR-T cells in limiting leptomeningeal acute leukemia2025
  5. 5PARP1 inhibition sensitizes AML to CD123 CAR-NK cells via immunophenotypic remodeling2025 · 1 citations